“Tanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway”, Clinics, vol. 70, no. 4, pp. 250–256, Apr. 2015, doi: 10.6061/clinics/2015(04)06.